Pleural Dynamics, Inc.
John Streeter is an experienced leader in technology and product development within the medical and consumer device sectors. Currently serving as the Chief Technology Officer and Co-Founder of Pleural Dynamics, Inc. since December 2019, John oversees company leadership, technology, and operations for an early-stage lung disease company. Additional roles include advisor and consultant for various medical device, pharmaceutical, and consumer device companies, focusing on technology and product development since February 2017. John previously held the position of Senior Vice President of R&D at Presage Biosciences, Inc., where leadership and development of combination products in oncology were key responsibilities. Earlier career highlights include advanced research roles at L'Oréal, VP of R&D at NUVAIRA, and director positions in product development at Cerapedics and Healionics, among others. John holds a B.S. in Chemical Engineering from the University of Colorado Boulder.
This person is not in any teams
This person is not in any offices
Pleural Dynamics, Inc.
Pleural Dynamics is a Minneapolis based medical device start-up focused on developing best in class solutions for chronic, recurrent fluid collections within the body. Our flagship product, ACES (the Automatic Continuous Effusion Shunt), is designed for the treatment of chronic recurrent pleural effusions. Chronic recurrent pleural effusions are a build-up of excess fluid between the lung and chest wall that compresses the lung and weighs on the diaphragm causing debilitating shortness of breath, irritating cough, poor quality of life, and short life expectancy. Recurrent pleural effusions affect approximately 660,000 new people in US and Europe each year and represents a $1.5B annual market opportunity for Pleural Dynamics. The current treatment options are cumbersome, costly, and based on decades old technology. ACES utilizes normal breathing motion to automatically pump pleural effusion fluid out of the chest and into the abdomen where it is quickly and safely reabsorbed by the body. This action provides continuous relief of patient symptoms while simultaneously decreasing caregiver labor, infection risk, and overall expense.